CuraGen Corporation

CuraGen has developed a genomic tool to assess the safety of new candidate drugs.

The Predictive Toxicogenomic Screen (PTS™) is a high throughput, cost-effective test system that screens and prioritizes new drug candidates based upon a predicted safety profile for the liver. This information is combined with potency information and chemical attributes to select the best new drug candidates, improving the efficiency and reducing the costs of drug development.

Further Information: http://www.curagen.com